Investegate |COMPASS Pathways Announcements | COMPASS Pathways : Open - label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Scientists have revealed a significant increase in the use of psilocybin therapy in small groups of cancer patients, which could be used to treat depression symptoms within two weeks of each day. A new study shows the effectiveness of the drug.

Source: investegate.co.uk
Published on 2021-10-20